Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 2
1989 3
1990 3
1991 3
1992 3
1993 5
1994 2
1995 3
1996 3
1997 11
1998 7
1999 7
2000 7
2001 7
2002 8
2003 6
2004 16
2005 12
2006 9
2007 10
2008 19
2009 17
2010 20
2011 27
2012 25
2013 39
2014 47
2015 45
2016 42
2017 50
2018 61
2019 53
2020 62
2021 66
2022 39
Text availability
Article attribute
Article type
Publication date

Search Results

661 results
Results by year
Filters applied: . Clear all
Page 1
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Simonneau G, et al. Eur Respir J. 2019 Jan 24;53(1):1801913. doi: 10.1183/13993003.01913-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545968 Free PMC article. Review.
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) 25 mmHg at rest, measured by right heart catheterisation. ...However, thi …
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arb …
Risk stratification and medical therapy of pulmonary arterial hypertension.
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV. Galiè N, et al. Eur Respir J. 2019 Jan 24;53(1):1801889. doi: 10.1183/13993003.01889-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545971 Free PMC article. Review.
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. ...
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of m
Definitions and diagnosis of pulmonary hypertension.
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Hoeper MM, et al. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032. J Am Coll Cardiol. 2013. PMID: 24355641 Free article. Review.
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure 25 mm Hg at rest, measured during right heart catheterization. There is still insufficient evidence to add an exercise criterion to this definition. The term pulmonary arterial
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure 25 mm Hg at rest, measured during right hear
Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week.
Maron BA, Kovacs G, Vaidya A, Bhatt DL, Nishimura RA, Mak S, Guazzi M, Tedford RJ. Maron BA, et al. J Am Coll Cardiol. 2020 Dec 1;76(22):2671-2681. doi: 10.1016/j.jacc.2020.10.007. J Am Coll Cardiol. 2020. PMID: 33243385 Free PMC article. Review.
Pulmonary hypertension (PH) is an independent risk factor for adverse clinical outcome, particularly in left heart disease (LHD) patients. Recent advances have clarified the mean pulmonary artery pressure (mPAP) range that is above normal and is associated wi
Pulmonary hypertension (PH) is an independent risk factor for adverse clinical outcome, particularly in left heart disease (LH
Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances.
Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn EM, Nicolls MR, Shlobin OA, Shah SJ, Kovacs G, Olschewski H, Rosenzweig EB. Maron BA, et al. Am J Respir Crit Care Med. 2021 Jun 15;203(12):1472-1487. doi: 10.1164/rccm.202012-4317SO. Am J Respir Crit Care Med. 2021. PMID: 33861689 Free PMC article.
The diagnosis and management of pulmonary arterial hypertension (PAH) includes several advances, such as a broader recognition of extrapulmonary vascular organ system involvement, validated point-of-care clinical assessment tools, and focus on the early initiation o …
The diagnosis and management of pulmonary arterial hypertension (PAH) includes several advances, such as a broader recognition …
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Shah SJ, et al. Circulation. 2016 Jul 5;134(1):73-90. doi: 10.1161/CIRCULATIONAHA.116.021884. Circulation. 2016. PMID: 27358439 Free PMC article. Review.
In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. ...Systemic inflammation also aff …
In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular re …
Transposition of the great arteries.
Warnes CA. Warnes CA. Circulation. 2006 Dec 12;114(24):2699-709. doi: 10.1161/CIRCULATIONAHA.105.592352. Circulation. 2006. PMID: 17159076 Review.
Long-term problems include coronary stenoses, distortion of the pulmonary arteries, dilatation of the neoaortic root, and aortic regurgitation. ...Associated defects, such as abnormalities of the tricuspid valve, ventricular septal defect, and pulmonary stenosis, oc …
Long-term problems include coronary stenoses, distortion of the pulmonary arteries, dilatation of the neoaortic root, and aortic regu …
Pulmonary arterial hypertension: epidemiology and registries.
McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M. McGoon MD, et al. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023. J Am Coll Cardiol. 2013. PMID: 24355642 Free article. Review.
Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in characterizing the presentation and natural history of the disease and provide a basis for prognostication. ...Considerations for future directions of registry studies includ …
Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in characterizing the presentation an …
Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting.
Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, Mahoney DW, Enriquez-Sarano M. Topilsky Y, et al. JACC Cardiovasc Imaging. 2019 Mar;12(3):433-442. doi: 10.1016/j.jcmg.2018.06.014. Epub 2018 Aug 15. JACC Cardiovasc Imaging. 2019. PMID: 30121261 Free article.
Isolated TR (without significant comorbidities, structural left valve disease, pulmonary hypertension, or overt cardiac cause) represented 8.1% of patients with greater or equal to moderate TR. ...
Isolated TR (without significant comorbidities, structural left valve disease, pulmonary hypertension, or overt cardiac cause) …
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.
Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium. Rhodes CJ, et al. Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5. Lancet Respir Med. 2019. PMID: 30527956 Free PMC article.
We tested for genome-wide association for pulmonary arterial hypertension in large international cohorts and assessed the contribution of associated regions to outcomes. ...INTERPRETATION: This is the first study to report that common genetic variation at loci in an …
We tested for genome-wide association for pulmonary arterial hypertension in large international cohorts and assessed the cont …
661 results